Concord Biotech Ltd

Concord Biotech Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Concord Biotech Ltd

₹ 1,542 0.95%
02 Jul - close price
concordbiotech.com BSE: 543960 NSE: CONCORDBIO
About

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Key Points

Busines segments
A) APIs[1] Co manufactures API's through fermentation and semi-synthetic processes, across therapeutic areas of immunosuppressants, oncology, and anti-infectives
B) Formulations[2] which are used in therapeutic areas of immunosuppressants, nephrology and anti-infective drugs for critical care.

Website BSE NSE
  • Market Cap ₹ 16,106 Cr.
  • Current Price ₹ 1,542
  • High / Low ₹ 1,725 / 900
  • Stock P/E 54.7
  • Book Value ₹ 146
  • Dividend Yield 0.57 %
  • ROCE 27.9 %
  • ROE 20.9 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 20.9%

Cons

  • Stock is trading at 10.6 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
181 159 241 273 195 262 241 319
116 121 129 144 123 143 135 185
Operating Profit 65 38 112 129 72 119 106 134
OPM % 36% 24% 46% 47% 37% 45% 44% 42%
8 6 9 12 7 8 8 11
Interest 1 1 1 1 1 1 0 0
Depreciation 14 13 14 14 13 13 14 14
Profit before tax 58 30 106 126 65 113 100 131
Tax % 26% 26% 26% 26% 25% 25% 26% 26%
43 22 79 94 48 84 75 97
EPS in Rs 45.32 2.14 7.56 8.94 4.63 8.08 7.13 9.29
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
340 436 512 617 713 853 1,017
195 256 308 289 439 509 585
Operating Profit 145 180 205 328 274 344 432
OPM % 43% 41% 40% 53% 38% 40% 42%
18 17 31 14 23 35 34
Interest 1 1 1 1 6 5 3
Depreciation 18 19 21 28 50 54 54
Profit before tax 144 178 213 313 241 320 409
Tax % 30% 33% 21% 25% 26% 26% 26%
100 118 169 235 179 238 305
EPS in Rs 105.66 124.48 177.65 247.44 187.76 22.76 29.13
Dividend Payout % 0% 21% 22% 0% 3% 30% 30%
Compounded Sales Growth
10 Years: %
5 Years: 18%
3 Years: 18%
TTM: 19%
Compounded Profit Growth
10 Years: %
5 Years: 20%
3 Years: 9%
TTM: 25%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 21%
3 Years: 19%
Last Year: 21%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 10 10 10 10 10 10 10
Reserves 585 673 761 990 1,098 1,282 1,515
22 9 52 89 62 32 10
69 72 118 94 144 191 164
Total Liabilities 685 763 941 1,183 1,313 1,515 1,699
189 230 240 546 573 593 575
CWIP 3 19 141 18 74 173 211
Investments 151 229 199 142 74 138 244
343 285 361 477 592 611 668
Total Assets 685 763 941 1,183 1,313 1,515 1,699

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
79 155 167 207 246 265
-42 -114 -195 -112 -158 -155
-37 -43 31 -100 -85 -99
Net Cash Flow 0 -1 3 -4 3 12

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 236 133 131 105 119 117 125
Inventory Days 381 310 312 503 434 430 331
Days Payable 210 112 201 152 185 190 150
Cash Conversion Cycle 407 331 242 456 368 357 306
Working Capital Days 275 186 160 196 179 163 169
ROCE % 27% 25% 32% 21% 26% 28%

Shareholding Pattern

Numbers in percentages

4 Recently
Sep 2023Dec 2023Mar 2024
44.08% 44.08% 44.08%
7.30% 7.00% 6.49%
8.12% 8.40% 8.41%
40.50% 40.52% 41.03%
No. of Shareholders 1,00,92787,48683,296

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls